Japan To Buy Additional 50M Doses Of Moderna COVID-19 Vaccine - TAKEDA PHARM CO LTD ORD by Takeda Pharmaceutical Co., Ltd. (OTC:TKPHF), Moderna (NASDAQ:MRNA), Takeda Pharmaceutical (NYSE:TAK)

Moderna Inc MRNA has announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co Ltd TAK will purchase and distribute an additional 50 million doses of Moderna's COVID-19 vaccine and its variant booster shot, if authorized, to begin delivery in 2022.
This new supply agreement is in addition to the prior arrangement for 50 million doses in 2021, resulting in 100 million doses for Japan.
Moderna is responsible for the manufacture and supply of the vaccine candidate, and Takeda is responsible for all import, local regulatory, development, and distribution activities.
The Japanese health ministry panel recently recommended lowering the current age restriction for Moderna's COVID-19 vaccine for emergency use in children aged between 12 to 17 years.
Price Action: MRNA shares are +1.57% at $318.50 during the premarket session on the last check Tuesday, while TAK shares closed at $16.88 on Monday.
Photo by hakan german from Pixabay